



**VGX Pharmaceuticals Announces Promotion of Bryan Kim, D.M.D.
to Vice President of Asian Operations**

Blue Bell, PA – July 1, 2007 –

VGX Pharmaceuticals today announced the promotion of Bryan Byong Jin Kim, D.M.D. to Vice President of Asian Operations. Dr. Kim has been serving as the Senior Director of Corporate Development. Since joining VGX in 2005, Dr. Kim has played an important role in various corporate development operations including the acquisition of VGX International, Inc. as well as the day-to-day management of this publicly-traded biopharmaceutical company in Korea. VGX International was added to a KOSPI 200 index in June, 2007. As VP of Asian Operations, Dr. Kim will oversee and coordinate VGX's strategic activities in Asia.

“Bryan has provided an invaluable service to our company,” said Dr. J. Joseph Kim, CEO and President. “As a member of our executive management team, he will continue to play an important role in our overall strategy to become a dynamic global biopharmaceutical company,”

Dr. Bryan Kim has had extensive experience in building successful organizations throughout his career. Prior to joining VGX, Dr. Kim was a successful private clinician and a Clinical Assistant Professor at the University of Pennsylvania, School of Dental Medicine, where he developed innovative clinical programs and directed important research projects granted by NIDH in microbiology and immunology.

Dr. Kim holds a Bachelor of Arts degree in Economics and a Bachelor of Science degree in Biological Science, both from University of California at Irvine and a Doctor of Dental Medicine degree from the University of Pennsylvania.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, and PENNVAX™-B, a DNA vaccine for preventing HIV infection, which is in Phase I clinical trials. In addition, VGX is planning to initiate Phase I clinical studies for VGX-1027, its lead compound for inflammatory diseases. VGX's research pipeline includes a new generation of SynCon™ DNA vaccines and therapeutics as well as the CELLECTRA™ electroporator, a patented DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com